Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 1
2019 1
2020 2
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.
Cristino AS, Nourse J, West RA, Sabdia MB, Law SC, Gunawardana J, Vari F, Mujaj S, Thillaiyampalam G, Snell C, Gough M, Keane C, Gandhi MK. Cristino AS, et al. Among authors: gough m. Blood. 2019 Dec 19;134(25):2261-2270. doi: 10.1182/blood.2019000889. Blood. 2019. PMID: 31856276 Free PMC article.
Improved relapse-free survival on aromatase inhibitors in breast cancer is associated with interaction between oestrogen receptor-α and progesterone receptor-b.
Snell CE, Gough M, Liu C, Middleton K, Pyke C, Shannon C, Woodward N, Hickey TE, Armes JE, Tilley WD. Snell CE, et al. Among authors: gough m. Br J Cancer. 2018 Nov;119(11):1316-1325. doi: 10.1038/s41416-018-0331-3. Epub 2018 Nov 9. Br J Cancer. 2018. PMID: 30410061 Free PMC article.
Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
Snell CE, Gough M, Middleton K, Hsieh M, Furnas L, Seidl B, Gibbons K, Pyke C, Shannon C, Woodward N, Armes JE. Snell CE, et al. Among authors: gough m. J Clin Pathol. 2017 Nov;70(11):954-960. doi: 10.1136/jclinpath-2016-204304. Epub 2017 Apr 17. J Clin Pathol. 2017. PMID: 28416639
Effective targeting of intact and proteolysed CDCP1 for imaging and treatment of pancreatic ductal adenocarcinoma.
Kryza T, Khan T, Puttick S, Li C, Sokolowski KA, Tse BW, Cuda T, Lyons N, Gough M, Yin J, Parkin A, Deryugina EI, Quigley JP, Law RHP, Whisstock JC, Riddell AD, Barbour AP, Wyld DK, Thomas PA, Rose S, Snell CE, Pajic M, He Y, Hooper JD. Kryza T, et al. Among authors: gough m. Theranostics. 2020 Mar 4;10(9):4116-4133. doi: 10.7150/thno.43589. eCollection 2020. Theranostics. 2020. PMID: 32226543 Free PMC article.
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Khan T, et al. Among authors: gough m. Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869. Cancers (Basel). 2020. PMID: 32260077 Free PMC article.
Feedback